Many entrepreneurs are pumping significant funds to chronic diseases’ research. They give funds to support research activities which will lead the cure and development of treatment plans for the diseases. Cancer is one of the chronic diseases. There are many cancer research as well as treatment centers. These facilities require huge funds for their operations. Eric Lefkofsky is one individual from Chicago who is working hard to ensure cancer is defeated.
Erik is a man who invests in technology to simplify activities. As a tech man, he has dedicated his knowledge to come up with treatment plans that are helpful to cancer patients. Eric is sure that the cost of research will continue to go down as technology improves. Way back in 2003, the cost of generating cell function was $100 million per genome. Currently, this cost has gone down to $5000, and Eric is certain it will continue to drop. It is essential to understand genomes to get to know how the body cells work against diseases.
Eric Lefkofsky co-founded Tempus which is a health tech company that builds infrastructure that modernizes cancer treatment. Tempus works closely with patients to ensure cancer is defeated. The company has come up with an operating system that is very effective in battling cancer. Eric together with his staff are using genomic sequencing and analyzing practices to assist cancer specialists to understand cancer tumors. Eric ensures that the company provides real-time, data-driven as well as personalized treatment decisions by analyzing genetic codes. They are helping patients with lung, pancreatic as well as breast cancer.
On top of co-founding Tempus, Eric and his wife are donating millions of dollars to support cancer research. They have founded Lefkofsky Family Foundation which works closely with many cancer research and treatment centers. Robert H. Lurie Comprehensive Cancer Center is one of the beneficiaries who has received $1million. The University of Michigan has also received $1.2 million for cancer research. Other recipients include Stanford University and New York’s Weill Cornell Medicine who have received $500000 and $250000 respectively.
On top of Eric’s Contribution, there has been a significant development in lung cancer causes research. In a study aimed at displaying gene-smoking interactions, three new lung cancer genetic biomarkers have been identified. The three novel single nucleotide polymorphisms in the DNA can be potential biomarkers which can be used to improve precision for researchers and will be helpful in the prediction of cancer treatment plans. The Dartmouth study was led by Yafang Li, Ph.D.